We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Asceneuron announced the receipt of a $2.2 million award from the Alzheimer's Drug Discovery Foundation (ADDF) for a first in human Phase I study of the Company's next generation O-GlcNAcase inhibitor, ASN51.